MRI of hepatic adenomatosis: initial observations with gadoxetic acid contrast agent in three patients.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 18430814.
- Also identified by DOI 10.2214/AJR.07.3198.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The purpose of our study was to describe the MR signal characteristics of histologically proven liver adenomatosis in three patients using gadoxetic acid, a newly developed liver-specific MR contrast agent. In all three patients, more than 100 liver adenomas revealed no metabolism of the new liver-specific contrast agent in the delayed phase. Because of absent or strongly reduced intracellular uptake of gadoxetic acid in all adenomas during delayed contrast-enhanced series, differentiation of adenomas from dysplastic or malignant lesions was not possible.
Medical subject headings
- Adenoma
- Contrast Media
- Gadolinium DTPA
- Liver Neoplasms
- Magnetic Resonance Imaging